Chia Nan University of Pharmacy & Science Institutional Repository:Item 310902800/34654
English  |  正體中文  |  简体中文  |  全文笔数/总笔数 : 18055/20253 (89%)
造访人次 : 24678713      在线人数 : 465
RC Version 7.0 © Powered By DSPACE, MIT. Enhanced by NTU Library IR team.
搜寻范围 查询小技巧:
  • 您可在西文检索词汇前后加上"双引号",以获取较精准的检索结果
  • 若欲以作者姓名搜寻,建议至进阶搜寻限定作者字段,可获得较完整数据
  • 进阶搜寻


    jsp.display-item.identifier=請使用永久網址來引用或連結此文件: https://ir.cnu.edu.tw/handle/310902800/34654


    標題: Clinical efficacy of SGLT2 inhibitors with different SGLT1/SGLT2 selectivity in cardiovascular outcomes among patients with and without heart failure: A systematic review and meta-analysis of randomized trials
    作者: Lee, Mei-Chuan
    Hua, Yi-Ming
    Yang, Chun-Ting
    Kuo, Fang-Hsiu
    Chang, Wei-Ting
    Tang, Hsin-Ju
    Toh, Han Siong
    Lin, Yu-Min
    Chen, Sih-Yao
    Chang, Hung-Yu
    Liao, Chia-Te
    貢獻者: Chi Mei Hospital
    National Cheng Kung University
    National Cheng Kung University
    Chi Mei Hospital
    National Cheng Kung University
    Southern Taiwan University of Science & Technology
    Chang Gung University of Science & Technology
    Chi Mei Hospital
    Department of Health and Nutrition, Chia Nan University of Pharmacy & Science
    National Yang Ming Chiao Tung University
    Cheng Hsin General Hospital
    關鍵字: cotransporter 2 inhibitors
    empagliflozin
    risk
    日期: 2022
    上傳時間: 2023-12-11 14:03:09 (UTC+8)
    出版者: LIPPINCOTT WILLIAMS & WILKINS
    摘要: Background:Some sodium-glucose co-transporter-2 (SGLT2) inhibitors showed benefits on heart failure (HF), but different SGLT2/SGLT1 selectivity might influence the treatment effect. This study aimed to meta-analyze the treatment effects of SGLT2 inhibitors and the diversity of receptor selectivity for patients with and without HF. Methods:Randomized controlled trials were searched in PubMed, Embase, Cochrane databases and ClinicalTrials.gov registry from inception to October 2020. The interest outcomes were analyzed with random-effects models and presented with a risk ratio (RR) and 95% confidence interval (CI). Subgroup analyses examined the treatment effects among SGLT2 inhibitors with different SGLT2/SGLT1 selectivity. Results:The final analyses included 10 trials and 52,607 patients. The RR of total cardiovascular (CV) death or hospitalization for HF (HHF) between SGLT2 inhibitors and placebo was 0.79 (95% CI 0.74-0.84, I-2 = 31%). With SGLT2 inhibitors, HF patients had reduced mortality risks (RR 0.89, 95% CI 0.80-0.99, I-2 = 0), and non-HF patients had lower risks of major adverse CV events (RR 0.92, 95% CI 0.85-0.99, I-2 = 0). The risk reduction of HHF was consistent in groups of HF (RR 0.72, 95% CI 0.64-0.80, I-2 = 8%) and non-HF (RR 0.74, 95% CI 0.61-0.89, I-2 = 0), but the effect of the low SGLT2/SGLT1 selectivity inhibitor was insignificant in non-HF patients. Conclusion:The efficacy of SGLT2 inhibitors on risk reduction of total CV death or HHF is consistent with the previous studies. The regimen is beneficial for reducing mortality in patients with HF and major adverse CV events in those without HF. Different SGLT2/SGLT1 selectivity may differ in the treatment effects in patients with and without HF.
    關聯: MEDICINE, v.101, n.51, e32489
    显示于类别:[保健營養系(所) ] 期刊論文

    文件中的档案:

    档案 描述 大小格式浏览次数
    index.html0KbHTML129检视/开启
    MD.0000000000032489.pdf1555KbAdobe PDF57检视/开启


    在CNU IR中所有的数据项都受到原著作权保护.

    TAIR相关文章

    DSpace Software Copyright © 2002-2004  MIT &  Hewlett-Packard  /   Enhanced by   NTU Library IR team Copyright ©   - 回馈